| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05575011 | A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec | PHASE1 | ACTIVE NOT_RECRUITING | 62 | — | — | Oct 10, 2022 | Nov 14, 2031 | Jul 9, 2025 | 17 | Belgium, Canada +7 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event.
| Arm | Type | Description |
|---|---|---|
| Part A: Cohort 1: BIIB115 Dose 1 | EXPERIMENTAL | Participants will receive a single dose of BIIB115, Dose 1, via IT bolus injection, on Day 1. |
| Part A: Cohort 2: BIIB115 Dose 2 | EXPERIMENTAL | Participants will receive a single dose of BIIB115, Dose 2, via IT bolus injection, on Day 1. |
| Part A: Cohort 3:BIIB115 Dose 3 | EXPERIMENTAL | Participants will receive a single dose of BIIB115, Dose 3, via IT bolus injection, on Day 1. |
| Part A: Cohort 4: BIIB115 Dose 4 | EXPERIMENTAL | Participants will receive a single dose of BIIB115, Dose 4, via IT bolus injection, on Day 1. |
| Part A: Cohorts 1-4: BIIB115-Matching Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of BIIB115-matching placebo, via IT bolus injection, on Day 1. |
| Part B: Cohort 5: BIIB115 Dose 3 | EXPERIMENTAL | Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 3, via IT bolus injection at two separate time points. |
| Part B: Cohort 6: BIIB115 Dose 4 | EXPERIMENTAL | Pediatric SMA participants previously treated with onasemnogene abeparvovec will receive two doses of BIIB115, Dose 4, via IT bolus injectionat two separate time points. |
| Part B: Long Term Extension (LTE): BIIB115 Dose 4 | EXPERIMENTAL | Pediatric SMA participants previously treated with onasemnogene abeparvovec who have completed Part B and are eligible will receive five doses of BIIB115, Dose 4, via IT bolus injection at separate time points for up to 60-month duration. |
| Name | Type | Description |
|---|---|---|
| BIIB115 | DRUG | Administered as specified in the treatment arm |
| BIIB115-Matching Placebo | DRUG | Administered as specified in the treatment arm |
Key Inclusion Criteria: Part A: * Male healthy participants aged 18 to 55 years, inclusive * Have a body mass index of 18 to 30 kilograms per meter square (kg/m\^2), inclusive * Must be in good health as determined by the investigator, based on medical history and screening evaluations Part B: *...